

Corrigendum

Corrigendum to “A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements”

[J. Pharm. Biomed. Anal. 33 (2003) 475–494]

A. Kümmerle^a, T. Krueger^b, M. Dusmet^b, C. Vallet^b, Y. Pan^b,
H.B. Ris^b, Laurent A. Decosterd^{a,*}

^a *Division de Pharmacologie Clinique, Département de Médecine, Laboratoire BH 18-218,
Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland*

^b *Service de Chirurgie Thoracique et Vasculaire, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland*

Available online 12 October 2004

The authors of the above mentioned article would like to make a correction to a section of text in their article.

The correction involves the replacement of the following text (from Section 3.6 “Applications of the method to animal studies”):

However, in the group perfused with 400 µg doxorubicin, a statistically significant difference ($P < 0.05$) was noticeable between the AG- and RG-ILP group, both for the AUCs_{0–20 min} (12 (9.9–13.6) versus 8.4 (7.0–10.1) mg h/L, respectively), and for the extraction ratio (0.08 (0.042–0.146) versus 0.18 (0.146–0.229), for AG- and RG-ILP, respectively.

with the corrected text:

In the group perfused with 400 µg doxorubicin, there is a trend (12 (9.9–13.6) versus 9.3 (7.3–11.8) ($P = 0.09$)) of the difference in AUCs_{0–20 min} determined with the AG- and RG-ILP mode, whereas the lung tissue extraction ratios obtained with these groups is statistically different: (0.08 (0.045–0.155) vs. 0.20 (0.115–0.256) for AG- and RG-ILP, respectively, $P < 0.05$).

doi of original article: [10.1016/S0731-7085\(03\)00300-5](https://doi.org/10.1016/S0731-7085(03)00300-5).

* Corresponding author. Tel.: +41 21 314 4272; fax: +41 21 314 4288.

E-mail address: laurentarthur.decosterd@chuv.hospvd.ch (L.A. Decosterd).